Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Current Therapeutic Research - Clinical and Experimental

Volumn 87, Issue , 2017, Pages 13-19

  Tobita, Hiroshi ^a   Sato, Shuichi ^a   Miyake, Tatsuya ^a   Ishihara, Shunji ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

cotransporter 2 inhibitor; dapagliflozin; nonalcoholic; open label; sodium glucose; steatohepatitis; type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 4; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLIMEPIRIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL; TYPE IV COLLAGEN 7S; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAT MASS; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; MASS; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; TOTAL BODY WATER; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

EID: 85028766250     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2017.07.002     Document Type: Article

References (39)

1. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006), S99–S112.
2. Ballestri, S., Zona, S., Targher, G., et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31 (2016), 936–944.
3. Lonardo, A., Bellentani, S., Argo, C.K., et al., Non-alcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 47 (2015), 997–1006.
4. Ballestri, S., Nascimbeni, F., Romagnoli, D., et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection–liver: the “musketeer” in the spotlight. Int J Mol Sci, 17, 2016, 355.
5. Watanabe, S., Hashimoto, E., Ikejima, K., et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 45 (2015), 363–377.
6. Shankar, S.S., Shankar, R.R., Railkar, R.A., Beals, C.R., Steinberg, H.O., Kelley, D.E., Early clinical detection of pharmacologic response in insulin action in a nondiabetic insulin-resistant population. Curr Ther Res Clin Exp 77 (2015), 83–89.
7. Hajiaghamohammadi, A.A., Ziaee, A., Oveisi, S., Masroor, H., Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepat Mon, 12, 2012, e6099.
8. Shyangdan, D., Clar, C., Ghouri, N., et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 15 (2011), 1–110.
9. Singh, S., Khera, R., Allen, A.M., et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic Review and Network Meta-analysis. Hepatology 62 (2015), 1417–1432.
10. Lombardi, R., Onali, S., Thorburn, D., et al. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev, 3, 2017 CD011640.
11. Kalra, S., Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 5 (2014), 355–366.
12. Honda, Y., Imajo, K., Kato, T., et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLOS ONE, 11, 2016, e0146337.
13. Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., Aso, Y., Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr, 8, 2016, 45.
14. Qiang, S., Nakatsu, Y., Seno, Y., et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr, 7, 2015, 104.
15. Shah, N.K., Deeb, W.E., Choksi, R., Epstein, B.J., Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 32 (2012), 80–94.
16. Terami, N., Ogawa, D., Tachibana, H., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLOS ONE, 9, 2014, e100777.
17. Chiba, Y., Yamada, T., Tsukita, S., et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLOS ONE, 11, 2016, e0150756.
18. Alberti, K.G., Eckel, R.H., Grundy, S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
19. Honda, T., Chen, S., Yonemoto, K., et al. Sedentary bout durations and metabolic syndrome among working adults: a prospective cohort study. BMC Public Health, 16, 2016, 888.
20. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino, Y., Nanjo, K., Tajima, N., et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Investig 1 (2010), 212–228.
21. Bugianesi, E., Rosso, C., Cortez-Pinto, H., How to diagnose NAFLD in 2016. J Hepatol 65 (2016), 643–644.
22. Brunt, E.M., Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. Int J Mol Sci, 17, 2016, E97 pii.
23. Pirlich, M., Schütz, T., Spachos, T., et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 32 (2000), 1208–1215.
24. Sumida, Y., Yoneda, M., Hyogo, H., et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46 (2011), 257–268.
25. Fields, D.A., Goran, M.I., Body composition techniques and the four-compartment model in children. J Appl Physiol. (1985) 89 (2000), 613–620.
26. Kriemler, S., Puder, J., Zahner, L., Roth, R., Braun-Fahrländer, C., Bedogni, G., Cross-validation of bioelectrical impedance analysis for the assessment of body composition in a representative sample of 6- to 13-year-old children. Eur J Clin Nutr 63 (2009), 619–626.
27. Bugianesi, E., Gentilcore, E., Manini, R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005), 1082–1090.
28. Coker, R.H., Williams, R.H., Yeo, S.E., et al. Visceral fat and adiponectin: associations with insulin resistance are tissue-specific in women. Metab Syndr Relat Disord 7 (2009), 61–67.
29. Kowdley, K.V., Belt, P., Wilson, L.A., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55 (2012), 77–85.
30. Bugianesi, E., Manzini, P., D'Antico, S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004), 179–187.
31. Jehn, M., Clark, J.M., Guallar, E., Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27 (2004), 2422–2428.
32. Hoki, T., Miyanishi, K., Tanaka, S., et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology 62 (2015), 751–761.
33. Adams, L.A., Crawford, D.H., Stuart, K., et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology 61 (2015), 1555–1564.
34. Chitturi, S., Abeygunasekera, S., Farrell, G.C., et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002), 373–379.
35. Pagano, G., Pacini, G., Musso, G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 35 (2002), 367–372.
36. Marchesini, G., Bugianesi, E., Forlani, G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003), 917–923.
37. Ono, M., Saibara, T., Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol 41 (2006), 725–732.
38. Koo, B.K., Kim, D., Joo, S.K., et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 66 (2017), 123–131.
39. Seko, Y., Sumida, Y., Tanaka, S., et al. Effect of sodium-glucose cotransporter 2 inhibitor on liver function tests in NAFLD patients with type 2 diabetes in Japan. Hepatol Res, 2016, 10.1111/hepr.12834.